UiPath, Inc (PATH) Fair Value & Analysis
Technology · US · Market cap $6.1B
Fair value as of: Jun 24, 2026
Analysis
UiPath, Inc (PATH) currently trades at $10.16, while our model-based Fair Value estimate is $8.83 — implying the stock looks roughly 13.1% overvalued today. We read business quality at 97/100 (high quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
UiPath, Inc. provides an automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. It offers the UiPath platform, an integrated enterprise software platform that enables AI agents, robots, people, and models to work together in coordinated workflows. The company's UiPath platform includes the UiPath Maestro process orchestration and process intelligence; UiPath agent builder; RPA and API automation; UiPath intelligent xtraction and processing; UiPath test cloud for testing and quality assurance; UiPath packaged and prebuilt agentic solutions; and centralized governance capabilities that apply across automations, AI agents, and manual tasks. It serves the financial services, healthcare, manufacturing, retail, and public sectors. The company was founded in 2005 and is headquartered in New York, New York.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is UiPath, Inc (PATH) undervalued?
What is the fair value of PATH?
What is the quality score of PATH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.